{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:05:27Z","timestamp":1791356727970,"version":"4.3.1"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T00:00:00Z","timestamp":1449705600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1038\/nrrheum.2016.166","type":"journal-article","created":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T10:26:11Z","timestamp":1449743171000},"page":"14-24","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":239,"title":["Interleukin-1 function and role in rheumatic disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Georg","family":"Schett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Dayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Manger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,10]]},"reference":[{"key":"BFnrrheum2016166_CR1","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.1073\/pnas.74.10.4624","volume":"74","author":"CA Dinarello","year":"1977","unstructured":"Dinarello, C. A., Renfer, L. & Wolff, S. M. Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc. Natl Acad. Sci. USA 74, 4624\u20134627 (1977).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum2016166_CR2","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/312458a0","volume":"312","author":"PT Lomedico","year":"1984","unstructured":"Lomedico, P. T. et al. Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature. 312, 458\u2013462 (1984).","journal-title":"Nature."},{"key":"BFnrrheum2016166_CR3","doi-asserted-by":"publisher","first-page":"7907","DOI":"10.1073\/pnas.81.24.7907","volume":"81","author":"PE Auron","year":"1984","unstructured":"Auron, P. E. et al. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc. Natl Acad. Sci. USA 81, 7907\u20137911 (1984).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum2016166_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1084\/jem.136.1.143","volume":"136","author":"I Gery","year":"1972","unstructured":"Gery, I. & Waksman, B. H. Potentiation of the T-lymphocyte response to mitogens. J. Exp. Med. 136, 143\u2013155 (1972).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum2016166_CR5","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1084\/jem.139.6.1369","volume":"139","author":"CA Dinarello","year":"1974","unstructured":"Dinarello, C. A., Goldin, N. P. & Wolff, S, M. Demonstration and characterization of two distinct human leukocytic pyrogens. J. Exp. Med. 139, 1269\u20131281 (1974).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum2016166_CR6","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/j.1471-4159.1982.tb12544.x","volume":"37","author":"CA Dinarello","year":"1981","unstructured":"Dinarello, C. A. & Bernheim, H. A. Ability of human leukocytic pyrogen to stimulate brain prostaglandin synthesis in vitro. J. Neurochem. 37, 702\u2013708 (1981).","journal-title":"J. Neurochem."},{"key":"BFnrrheum2016166_CR7","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1084\/jem.145.5.1399","volume":"145","author":"JM Dayer","year":"1977","unstructured":"Dayer, J. M., Robinson, D. R & Krane, S. M. Prostaglandin production by rheumatoid synovial cells: stimulation by a factor from human mononuclear cells. J. Exp. Med. 145, 1399\u20131404 (1977).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum2016166_CR8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1126\/science.177.4051.793","volume":"177","author":"JE Horton","year":"1972","unstructured":"Horton, J. E. et al. Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes. Science 177, 793\u2013795 (1972).","journal-title":"Science"},{"key":"BFnrrheum2016166_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1126\/science.188134","volume":"195","author":"JM Dayer","year":"1977","unstructured":"Dayer, J. M., Graham, R., Russell, G. & Krane, S. M. Collagenase production by rheumatoid synovial cells: stimulation by a human lymphocyte factor. Science 195, 181\u2013183 (1977).","journal-title":"Science"},{"key":"BFnrrheum2016166_CR10","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/0006-291X(80)90082-0","volume":"16","author":"J Saklatvala","year":"1980","unstructured":"Saklatvala, J. & Dingle, J. T. Identification of catabolin, a protein from synovium which induces degradation of cartilage in organ culture. Biochem. Biophys. Res. Commun. 16, 1225\u20131231 (1980).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrrheum2016166_CR11","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1073\/pnas.78.4.2474","volume":"78","author":"SB Mizel","year":"1981","unstructured":"Mizel, S. B, Dayer, J.-M., Krane, S. M. & Mergenhagen, S. E. Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin 1). Proc. Natl Acad. Sci. USA 78, 2474\u20132477 (1981).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum2016166_CR12","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1056\/NEJM198303103081002","volume":"10","author":"V Baracos","year":"1983","unstructured":"Baracos, V., Rodemann, H. P., Dinarello, C. A. & Goldberg, A. L. Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1) \u2014 a mechanism for the increased degradation of muscle proteins during fever. N. Engl. J. Med. 10, 553\u2013558 (1983).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2016166_CR13","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.4049\/jimmunol.123.6.2928","volume":"123","author":"LA Aarden","year":"1979","unstructured":"Aarden, L. A. et al. Revised nomenclature for antigen nonspecific T cell proliferation and helper factors. J. Immunol. 123, 2928\u20132929 (1979).","journal-title":"J. Immunol."},{"key":"BFnrrheum2016166_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-immunol-032414-112306","volume":"33","author":"MG Netea","year":"2015","unstructured":"Netea, M. G., van de Veerdonk, F. L., van der Meer, J. W., Dinarello, C. A. & Joosten, L. A. Inflammasome-independent regulation of IL-1-family cytokines. Annu. Rev. Immunol. 33, 49\u201377 (2015).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrrheum2016166_CR15","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/ni1110-973","volume":"11","author":"C Dinnarello","year":"2010","unstructured":"Dinnarello, C. et al. IL-1 family nomenclature. Nat. Immunol. 11, 973 (2010).","journal-title":"Nat. Immunol."},{"key":"BFnrrheum2016166_CR16","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","volume":"39","author":"C Garlanda","year":"2013","unstructured":"Garlanda, C., Dinarello, C. A. & Mantovani, A. The interleukin-1 family: back to the future. Immunity 39, 1003\u20131018 (2013).","journal-title":"Immunity"},{"key":"BFnrrheum2016166_CR17","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1073\/pnas.1121534109","volume":"109","author":"FL van de Veerdonk","year":"2012","unstructured":"van de Veerdonk, F. L. et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc. Natl Acad. Sci. USA 109, 3001\u20133005 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum2016166_CR18","doi-asserted-by":"publisher","unstructured":"Rudloff, I. et al. Interleukin 38 exerts anti-inflammatory functions and is associated with disease activity in systemic lupus erythematosus. Arthritis Rheumatol. http:\/\/dx.doi.org\/10.1002\/art.39328 (2015).","DOI":"10.1002\/art.39328"},{"key":"BFnrrheum2016166_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/370270a0","volume":"370","author":"KP Wilson","year":"1994","unstructured":"Wilson, K. P. et al. Structure and mechanism of interleukin-1\u03b2 converting enzyme. Nature 370, 270\u2013275 (1994).","journal-title":"Nature"},{"key":"BFnrrheum2016166_CR20","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/356768a0","volume":"356","author":"NA Thornberry","year":"1992","unstructured":"Thornberry, N. A. et al. A novel heterodimeric cysteine protease is required for interleukin-1\u03b2 processing in monocytes. Nature 356, 768\u2013774 (1992).","journal-title":"Nature"},{"key":"BFnrrheum2016166_CR21","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nm1603","volume":"13","author":"CJ Chen","year":"2007","unstructured":"Chen, C. J. et al. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat. Med. 13, 851\u2013856 (2007).","journal-title":"Nat. Med."},{"key":"BFnrrheum2016166_CR22","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.immuni.2015.06.003","volume":"42","author":"IS Afonina","year":"2015","unstructured":"Afonina, I. S., M\u00fcller, C., Martin, S. J. & Beyaert, R. Proteolytic processing of Interleukin-1 family cytokines: variations on a common theme. Immunity 42, 991\u20131004 (2015).","journal-title":"Immunity"},{"key":"BFnrrheum2016166_CR23","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.1184003","volume":"327","author":"K Schroder","year":"2010","unstructured":"Schroder, K., Zhou, R. & Tschopp, J. The NLRP3 inflammasome: a sensor for metabolic danger? Science 327, 296\u2013300 (2010).","journal-title":"Science"},{"key":"BFnrrheum2016166_CR24","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1182\/blood-2008-03-146720","volume":"113","author":"MG Netea","year":"2009","unstructured":"Netea, M. G. et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1\u03b2 in monocytes and macrophages. Blood 113, 2324\u20132335 (2009).","journal-title":"Blood"},{"key":"BFnrrheum2016166_CR25","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.4049\/jimmunol.176.7.3877","volume":"176","author":"D Ferrari","year":"2006","unstructured":"Ferrari, D. et al. The P2X7 receptor: a key player in IL-1 processing and release. J. Immunol. 176, 3877\u20133883 (2006).","journal-title":"J. Immunol."},{"key":"BFnrrheum2016166_CR26","doi-asserted-by":"publisher","first-page":"4987","DOI":"10.4049\/jimmunol.172.8.4987","volume":"172","author":"A Elssner","year":"2004","unstructured":"Elssner, A. et al. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1\u03b2 processing and release. J. Immunol. 172, 4987\u20134994 (2004).","journal-title":"J. Immunol."},{"key":"BFnrrheum2016166_CR27","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.4049\/jimmunol.1401624","volume":"194","author":"M Karmakar","year":"2015","unstructured":"Karmakar, M. et al. Neutrophil IL-1\u03b2 processing induced by pneumolysin is mediated by the NLRP3\/ASC inflammasome and caspase-1 activation and is dependent on K+ efflux. J. Immunol. 194, 1763\u20131775 (2015).","journal-title":"J. Immunol."},{"key":"BFnrrheum2016166_CR28","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.celrep.2014.06.028","volume":"8","author":"KW Chen","year":"2014","unstructured":"Chen, K. W. et al. The neutrophil NLRC4 inflammasome selectively promotes IL-1\u03b2 maturation without pyroptosis during acute Salmonella challenge. Cell Rep. 8, 570\u2013582 (2014).","journal-title":"Cell Rep."},{"key":"BFnrrheum2016166_CR29","doi-asserted-by":"publisher","first-page":"6261","DOI":"10.1073\/pnas.96.11.6261","volume":"96","author":"C Coeshott","year":"1999","unstructured":"Coeshott, C. et al. Converting enzyme-independent release of tumor necrosis factor \u03b1 and IL-1\u03b2 from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc. Natl Acad. Sci. USA 96, 6261\u20136266 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum2016166_CR30","doi-asserted-by":"publisher","first-page":"6568","DOI":"10.4049\/jimmunol.167.11.6568","volume":"167","author":"S Sugawara","year":"2001","unstructured":"Sugawara, S. et al. Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. J. Immunol. 167, 6568\u20136575 (2001).","journal-title":"J. Immunol."},{"key":"BFnrrheum2016166_CR31","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1084\/jem.181.5.1917","volume":"181","author":"M Irmler","year":"1995","unstructured":"Irmler, M. et al. Granzyme A is an interleukin 1\u03b2-converting enzyme. J. Exp. Med. 181, 1917\u20131922 (1995).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum2016166_CR32","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.bbrc.2008.12.161","volume":"379","author":"C Herzog","year":"2009","unstructured":"Herzog, C. et al. Meprin A and meprin \u03b1 generate biologically functional IL-1\u03b2 from pro-IL-1\u03b2. Biochem. Biophys. Res. Commun. 379, 904\u2013908 (2009).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrrheum2016166_CR33","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nm.3547","volume":"20","author":"C Schauer","year":"2014","unstructured":"Schauer, C. et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat. Med. 20, 511\u2013517 (2014).","journal-title":"Nat. Med."},{"key":"BFnrrheum2016166_CR34","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.4049\/jimmunol.1102048","volume":"187","author":"P Rider","year":"2011","unstructured":"Rider, P. et al. IL-1\u03b1 and IL-1\u03b2 recruit different myeloid cells and promote different stages of sterile inflammation. J. Immunol. 187, 4835\u20134843 (2011).","journal-title":"J. Immunol."},{"key":"BFnrrheum2016166_CR35","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1073\/pnas.0915018107","volume":"107","author":"I Cohen","year":"2010","unstructured":"Cohen, I. et al. Differential release of chromatin-bound IL-1\u03b1 discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc. Natl Acad. Sci. USA 107, 2574\u20132579 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum2016166_CR36","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.4049\/jimmunol.139.5.1541","volume":"139","author":"P Seckinger","year":"1987","unstructured":"Seckinger, P. et al. A urine inhibitor of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor alpha. J. Immunol. 139, 1541\u20131545 (1987).","journal-title":"J. Immunol."},{"key":"BFnrrheum2016166_CR37","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1056\/NEJM200009073431011","volume":"343","author":"CA Dinarello","year":"2000","unstructured":"Dinarello, C. A. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N. Engl. J. Med. 343, 732\u2013734 (2000).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2016166_CR38","doi-asserted-by":"publisher","first-page":"11982","DOI":"10.1074\/jbc.M700356200","volume":"282","author":"PH Kuhn","year":"2007","unstructured":"Kuhn, P. H. et al. Regulated intramembrane proteolysis of the interleukin-1 receptor II by \u03b1-, \u03b2-, and \u03b3-secretase. J. Biol. Chem. 282, 11982\u201311995 (2007).","journal-title":"J. Biol. Chem."},{"key":"BFnrrheum2016166_CR39","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1084\/jem.183.4.1841","volume":"183","author":"F Re","year":"1996","unstructured":"Re, F. et al. Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface 'receptor' with anti-interleukin-1 function. J. Exp. Med. 183, 1841\u20131850 (1996).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum2016166_CR40","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1126\/science.8332913","volume":"261","author":"F Colotta","year":"1993","unstructured":"Colotta, F. et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 261, 472\u2013475 (1993).","journal-title":"Science"},{"key":"BFnrrheum2016166_CR41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1172\/JCI118045","volume":"96","author":"D Burger","year":"1995","unstructured":"Burger, D., Chicheportiche, R., Giri, J. G. & Dayer, J. M. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J. Clin. Invest. 96, 38\u201341 (1995).","journal-title":"J. Clin. Invest."},{"key":"BFnrrheum2016166_CR42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nri3365","volume":"13","author":"H Spits","year":"2013","unstructured":"Spits, H. et al. Innate lymphoid cells \u2014 a proposal for uniform nomenclature. Nat. Rev. Immunol. 13, 145\u2013149 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnrrheum2016166_CR43","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm.3423","volume":"20","author":"HY Kim","year":"2014","unstructured":"Kim, H. Y. et al. Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nat. Med. 20, 54\u201361 (2014).","journal-title":"Nat. Med."},{"key":"BFnrrheum2016166_CR44","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1084\/jem.20060285","volume":"203","author":"C Sutton","year":"2006","unstructured":"Sutton, C. et al. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 203, 1685\u20131691 (2006).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum2016166_CR45","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.immuni.2009.02.007","volume":"30","author":"Y Chung","year":"2009","unstructured":"Chung, Y. et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 30, 576\u2013587 (2009).","journal-title":"Immunity"},{"key":"BFnrrheum2016166_CR46","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/ni1496","volume":"8","author":"EV Acosta-Rodriguez","year":"2007","unstructured":"Acosta-Rodriguez, E. V. et al. Interleukin 1\u03b2 and 6 but not transforming growth factor-\u03b2 are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 8, 942\u2013949 (2007).","journal-title":"Nat. Immunol."},{"key":"BFnrrheum2016166_CR47","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nature10957","volume":"484","author":"CE Zielinski","year":"2012","unstructured":"Zielinski, C. E. et al. Pathogen-induced human TH17 cells produce IFN-\u03b3 or IL-10 and are regulated by IL-1\u03b2. Nature 484, 514\u2013518 (2012).","journal-title":"Nature"},{"key":"BFnrrheum2016166_CR48","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1182\/blood-2008-05-155408","volume":"112","author":"C Chizzolini","year":"2008","unstructured":"Chizzolini, C. et al. Prostaglandin E2 (PGE2) synergistically with interleukin-23 (IL-23) favors human TH17 expansion. Blood 112, 3696\u20133703 (2008).","journal-title":"Blood"},{"key":"BFnrrheum2016166_CR49","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/icb.2009.56","volume":"87","author":"C Chizzolini","year":"2009","unstructured":"Chizzolini, C. & Brembilla, N. C. Prostaglandin E2: igniting the fire. Immunol. Cell Biol. 87, 510\u2013511 (2009).","journal-title":"Immunol. Cell Biol."},{"key":"BFnrrheum2016166_CR50","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.immuni.2009.08.001","volume":"31","author":"CE Sutton","year":"2009","unstructured":"Sutton, C. E. et al. Interleukin-1 and IL-23 induce innate IL-17 production from \u03b3\u03b4 T cells, amplifying Th17 responses and autoimmunity. Immunity 31, 331\u2013341 (2009).","journal-title":"Immunity"},{"key":"BFnrrheum2016166_CR51","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1084\/jem.20080397","volume":"205","author":"L Cosmi","year":"2008","unstructured":"Cosmi, L. et al. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J. Exp. Med. 205, 1903\u20131916 (2008).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum2016166_CR52","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1002\/eji.200940257","volume":"40","author":"L Maggi","year":"2010","unstructured":"Maggi, L. et al. CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC. Eur. J. Immunol. 40, 2174\u20132181 (2010).","journal-title":"Eur. J. Immunol."},{"key":"BFnrrheum2016166_CR53","first-page":"563","volume":"5","author":"JM Dayer","year":"1994","unstructured":"Dayer, J. M. & Burger, D. Interleukin-1, tumor necrosis factor and their specific inhibitors. Eur. Cytokine Netw. 5, 563\u2013571 (1994).","journal-title":"Eur. Cytokine Netw."},{"key":"BFnrrheum2016166_CR54","doi-asserted-by":"publisher","first-page":"11742","DOI":"10.1073\/pnas.0610812104","volume":"104","author":"J Zwerina","year":"2007","unstructured":"Zwerina, J. et al. TNF-induced structural joint damage is mediated by IL-1. Proc. Natl Acad. Sci. USA 104, 11742\u201311747 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum2016166_CR55","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.berh.2003.09.009","volume":"18","author":"JM Dayer","year":"2004","unstructured":"Dayer, J. M. The process of identifying and understanding cytokines: from basic studies to treating rheumatic diseases. Best Pract. Res. Clin. Rheumatol. 18, 31\u201345 (2004).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"BFnrrheum2016166_CR56","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/306378a0","volume":"306","author":"M Gowen","year":"1983","unstructured":"Gowen, M., Wood, D. D., Ihrie, E. J., McGuire, M. K. & Russell, R. G. An interleukin 1 like factor stimulates bone resorption in vitro. Nature 306, 378\u2013380 (1983).","journal-title":"Nature"},{"key":"BFnrrheum2016166_CR57","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1172\/JCI200523394","volume":"115","author":"S Wei","year":"2005","unstructured":"Wei, S., Kitaura, H., Zhou, P., Ross, F. P. & Teitelbaum, S. L. IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest. 115, 282\u2013290 (2005).","journal-title":"J. Clin. Invest."},{"key":"BFnrrheum2016166_CR58","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/334698a0","volume":"334","author":"SH Ferreira","year":"1988","unstructured":"Ferreira, S. H., Lorenzetti, B. B., Bristow, A. F. & Poole, S. Interleukin-1\u03b2 as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature 334, 698\u2013700 (1988).","journal-title":"Nature"},{"key":"BFnrrheum2016166_CR59","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1084\/jem.20070157","volume":"204","author":"H Blumberg","year":"2007","unstructured":"Blumberg, H. et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J. Exp. Med. 204, 2603\u20132614 (2007).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum2016166_CR60","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1128\/IAI.58.10.3319-3324.1990","volume":"58","author":"BJ Kullberg","year":"1990","unstructured":"Kullberg, B. J., van ' t Wout, J. W. & van Furth, R. Role of granulocytes in increased host resistance to Candida albicans induced by recombinant interleukin-1. Infect. Immun. 58, 3319\u20133324 (1990).","journal-title":"Infect. Immun."},{"key":"BFnrrheum2016166_CR61","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.4049\/jimmunol.176.7.4337","volume":"176","author":"N Oz\u00f6ren","year":"2006","unstructured":"Oz\u00f6ren, N. et al. Distinct roles of TLR2 and the adaptor ASC in IL-1\u03b2\/IL-18 secretion in response to Listeria monocytogenes. J. Immunol. 176, 4337\u20134342 (2006).","journal-title":"J. Immunol."},{"key":"BFnrrheum2016166_CR62","doi-asserted-by":"publisher","first-page":"7558","DOI":"10.4049\/jimmunol.180.11.7558","volume":"180","author":"SE Warren","year":"2008","unstructured":"Warren, S. E., Mao, D. P., Rodriguez, A. E., Miao, E. A. & Aderem, A. Multiple Nod-like receptors activate caspase 1 during Listeria monocytogenes infection. J. Immunol. 180, 7558\u20137564 (2008).","journal-title":"J. Immunol."},{"key":"BFnrrheum2016166_CR63","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1084\/jem.20060206","volume":"203","author":"M Lara-Tejero","year":"2006","unstructured":"Lara-Tejero, M. et al. Role of the caspase-1 inflammasome in Salmonella typhimurium pathogenesis. J. Exp. Med. 203, 1407\u20131412 (2006).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum2016166_CR64","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1086\/315771","volume":"182","author":"NP Juffermans","year":"2000","unstructured":"Juffermans, N. P. et al. Interleukin-1 signaling is essential for host defense during murine pulmonary tuberculosis. J. Infect. Dis. 182, 902\u2013908 (2000).","journal-title":"J. Infect. Dis."},{"key":"BFnrrheum2016166_CR65","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1002\/art.10578","volume":"46","author":"G Nuki","year":"2002","unstructured":"Nuki, G. et al. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 2838\u20132846 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016166_CR66","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1001\/jama.1994.03510470040032","volume":"271","author":"CJ Fisher Jr","year":"1994","unstructured":"Fisher, C. J. Jr et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 271, 1836\u20131843 (1994).","journal-title":"JAMA"},{"key":"BFnrrheum2016166_CR67","first-page":"2134","volume":"12","author":"G Cavalli","year":"2015","unstructured":"Cavalli, G. & Dinarello, C. A. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford) 12, 2134\u20132144 (2015).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2016166_CR68","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.4049\/jimmunol.135.6.3669","volume":"135","author":"B Manger","year":"1985","unstructured":"Manger, B., Weiss, A., Weyand, C., Goronzy, J. & Stobo, J. D. T cell activation: differences required for IL 2 production by nonactivated and activated T cells. J. Immunol. 135, 3669\u20133673 (1985).","journal-title":"J. Immunol."},{"key":"BFnrrheum2016166_CR69","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/bor.0000174210.78449.6b","volume":"17","author":"S Stojanov","year":"2005","unstructured":"Stojanov, S. & Kastner, D. L. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr. Opin. Rheumatol. 17, 586\u2013599 (2005).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum2016166_CR70","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/ard.2005.038091","volume":"65","author":"M Rynne","year":"2006","unstructured":"Rynne, M., Maclean, C., Bybee, A., McDermott, M. F. & Emery, P. Hearing improvement in a patient with variant Muckle\u2013Wells syndrome in response to interleukin 1 receptor antagonism. Ann. Rheum. Dis. 65, 533\u2013534 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016166_CR71","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/art.20953","volume":"52","author":"DJ Lovell","year":"2005","unstructured":"Lovell, D. J., Bowyer, S. L. & Solinger, A. M. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum. 52, 1283\u20131286 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016166_CR72","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJMoa055137","volume":"355","author":"R Goldbach-Mansky","year":"2006","unstructured":"Goldbach-Mansky, R. et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1\u03b2 inhibition. N. Engl. J. Med. 355, 581\u2013592 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2016166_CR73","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/art.20033","volume":"50","author":"PN Hawkins","year":"2004","unstructured":"Hawkins, P. N., Lachmann, H. J., Aganna, E. & McDermott, M. F. Spectrum of clinical features in Muckle\u2013Wells syndrome and response to anakinra. Arthritis Rheum. 50, 607\u2013612 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016166_CR74","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1136\/ard.2007.071498","volume":"66","author":"LM Kuijk","year":"2007","unstructured":"Kuijk, L. M., Govers, A. M., Frenkel, J. & Hofhuis, W. J. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann. Rheum. Dis. 66, 1545\u20131546 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016166_CR75","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0025-6196(11)63565-9","volume":"72","author":"NM Lindor","year":"1997","unstructured":"Lindor, N. M., Arsenault, T. M., Solomon, H., Seidman, C. E. & McEvoy, M. T. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin. Proc. 72, 611\u2013615 (1997).","journal-title":"Mayo Clin. Proc."},{"key":"BFnrrheum2016166_CR76","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/j.1365-2133.2009.09404.x","volume":"161","author":"M Brenner","year":"2009","unstructured":"Brenner, M., Ruzicka, T., Plewig, G., Thomas, P. & Herzer, P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br. J. Dermatol. 161, 1199\u20131201 (2009).","journal-title":"Br. J. Dermatol."},{"key":"BFnrrheum2016166_CR77","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1056\/NEJMoa0807865","volume":"360","author":"I Aksentijevich","year":"2009","unstructured":"Aksentijevich, I. et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 360, 2426\u20132437 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2016166_CR78","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1002\/art.23475","volume":"58","author":"M Gattorno","year":"2008","unstructured":"Gattorno, M. et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 58, 1516\u20131520 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016166_CR79","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s10545-006-0408-7","volume":"29","author":"M Cailliez","year":"2006","unstructured":"Cailliez, M. et al. Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. J. Inherit Metab. Dis. 29, 763 (2006).","journal-title":"J. Inherit Metab. Dis."},{"key":"BFnrrheum2016166_CR80","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1074\/jbc.M110.139048","volume":"286","author":"C Schorn","year":"2011","unstructured":"Schorn, C. et al. Sodium overload and water influx activate the NALP3 inflammasome. J. Biol. Chem. 286, 35\u201341 (2011).","journal-title":"J. Biol. Chem."},{"key":"BFnrrheum2016166_CR81","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon, F., P\u00e9trilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237\u2013241 (2006).","journal-title":"Nature"},{"key":"BFnrrheum2016166_CR82","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1002\/art.10326","volume":"46","author":"C Schiltz","year":"2002","unstructured":"Schiltz, C. et al. Monosodium urate monohydrate crystal-induced inflammation in vivo: quantitative histomorphometric analysis of cellular events. Arthritis Rheum. 46, 1643\u20131650 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016166_CR83","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1002\/art.27667","volume":"62","author":"LA Joosten","year":"2010","unstructured":"Joosten, L. A. et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1\u03b2 production via the ASC\/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum. 62, 3237\u20133248 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016166_CR84","doi-asserted-by":"publisher","first-page":"R28","DOI":"10.1186\/ar2143","volume":"9","author":"A So","year":"2007","unstructured":"So, A., De Smedt, T., Revaz, S. & Tschopp, J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9, R28 (2007).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2016166_CR85","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/acr.21989","volume":"65","author":"P Ghosh","year":"2013","unstructured":"Ghosh, P., Cho, M., Rawat, G., Simkin, P. A. & Gardner, G. C. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res. (Hoboken) 65, 1381\u20131384 (2013).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrrheum2016166_CR86","doi-asserted-by":"publisher","first-page":"R123","DOI":"10.1186\/ar4303","volume":"15","author":"S Ottaviani","year":"2013","unstructured":"Ottaviani, S. et al. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res. Ther. 15, R123 (2013).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2016166_CR87","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/acr.21690","volume":"64","author":"HR Schumacher Jr","year":"2012","unstructured":"Schumacher, H. R. Jr et al. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a Phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res. (Hoboken) 64, 1462\u20131470 (2012).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrrheum2016166_CR88","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1093\/rheumatology\/ket114","volume":"52","author":"E Mitha","year":"2013","unstructured":"Mitha, E. et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, Phase 3, randomized, placebo-controlled trial. Rheumatology (Oxford) 52, 1285\u20131292 (2013).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2016166_CR89","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","volume":"71","author":"N Schlesinger","year":"2012","unstructured":"Schlesinger, N. et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann. Rheum. Dis. 71, 1839\u20131848 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016166_CR90","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jbspin.2011.12.017","volume":"79","author":"M Couderc","year":"2012","unstructured":"Couderc, M., Mathieu, S., Glace, B. & Soubrier, M. Efficacy of anakinra in articular chondrocalcinosis: report of three cases. Joint Bone Spine 79, 330\u2013331 (2012).","journal-title":"Joint Bone Spine"},{"key":"BFnrrheum2016166_CR91","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1136\/annrheumdis-2012-202380","volume":"72","author":"P Zufferey","year":"2013","unstructured":"Zufferey, P. & So, A. A pilot study of IL-1 inhibition in acute calcific periarthritis of the shoulder. Ann. Rheum. Dis. 72, 465\u2013467 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016166_CR92","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(87)91854-X","volume":"2","author":"AM Prieur","year":"1987","unstructured":"Prieur, A. M., Kaufmann, M. T., Griscelli, C. & Dayer, J. M. Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. Lancet 2, 1240\u20131242 (1987).","journal-title":"Lancet"},{"key":"BFnrrheum2016166_CR93","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/art.21061","volume":"52","author":"AA Fitzgerald","year":"2005","unstructured":"Fitzgerald, A. A., Leclercq, S. A., Yan, A., Homik, J. E. & Dinarello, C. A. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 52, 1794\u20131803 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016166_CR94","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1136\/ard.2004.026617","volume":"64","author":"FM Vasques Godinho","year":"2004","unstructured":"Vasques Godinho, F. M., Parreira Santos, M. J. & Canas da Silva, J. Refractory adult onset Still's disease successfully treated with anakinra. Ann. Rheum. Dis. 64, 647\u2013648 (2004).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016166_CR95","doi-asserted-by":"publisher","first-page":"e1554","DOI":"10.1097\/MD.0000000000001554","volume":"94","author":"F Ortiz-Sanju\u00e1n","year":"2015","unstructured":"Ortiz-Sanju\u00e1n, F. et al. Efficacy of anakinra in refractory adult-onset Still's disease: multicenter study of 41 patients and literature review. Medicine (Baltimore). 94, e1554 (2015).","journal-title":"Medicine (Baltimore)."},{"key":"BFnrrheum2016166_CR96","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/ard.2007.076034","volume":"67","author":"T Lequerr\u00e9","year":"2008","unstructured":"Lequerr\u00e9, T. et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann. Rheum. Dis. 67, 302\u2013308 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016166_CR97","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/art.23437","volume":"58","author":"M Gattorno","year":"2008","unstructured":"Gattorno, M. et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 58, 1505\u20131515 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016166_CR98","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/rheumatology\/ken030","volume":"47","author":"V Ohlsson","year":"2008","unstructured":"Ohlsson, V. et al. Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology (Oxford) 47, 555\u2013556 (2008).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2016166_CR99","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1084\/jem.191.2.313","volume":"191","author":"R Horai","year":"2000","unstructured":"Horai, R. et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191, 313\u2013320 (2000).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum2016166_CR100","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/art.1780260806","volume":"26","author":"DD Wood","year":"1983","unstructured":"Wood, D. D., Ihrie, E. J., Dinarello, C. A. & Cohen, P. L. Isolation of an interleukin-1-like factor from human joint effusions. Arthritis Rheum. 26, 975\u2013983 (1983).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016166_CR101","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0090-1229(92)90243-H","volume":"65","author":"AE Koch","year":"1992","unstructured":"Koch, A. E. et al. Expression of interleukin-1 and interleukin-1 receptor antagonist by human rheumatoid synovial tissue macrophages. Clin. Immunol. Immunopathol. 65, 23\u201329 (1992).","journal-title":"Clin. Immunol. Immunopathol."},{"key":"BFnrrheum2016166_CR102","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.4049\/jimmunol.149.3.1054","volume":"149","author":"GS Firestein","year":"1992","unstructured":"Firestein, G. S. et al. IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium. J. Immunol. 149, 1054\u20131062 (1992).","journal-title":"J. Immunol."},{"key":"BFnrrheum2016166_CR103","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/art.1780390513","volume":"39","author":"LA Joosten","year":"1996","unstructured":"Joosten, L. A., Helsen, M. M., van de Loo, F. A. & van den Berg, W. B. Anticytokine treatment of established type II collagen-induced arthritis in DBA\/1 mice: a comparative study using anti-TNF\u03b1, anti-IL-1\u03b1\/\u03b2, and IL-1Ra. Arthritis Rheum. 39, 797\u2013809 (1996).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016166_CR104","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/art.11487","volume":"50","author":"J Zwerina","year":"2004","unstructured":"Zwerina, J. et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum. 50, 277\u2013290 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016166_CR105","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","volume":"41","author":"B Bresnihan","year":"1998","unstructured":"Bresnihan, B. et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41, 2196\u20132204 (1998).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016166_CR106","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1136\/ard.2003.016014","volume":"63","author":"SB Cohen","year":"2004","unstructured":"Cohen, S. B. et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann. Rheum. Dis. 63, 1062\u20131068 (2004).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016166_CR107","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/art.10141","volume":"46","author":"S Cohen","year":"2002","unstructured":"Cohen, S. et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 614\u2013624 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016166_CR108","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/00002281-200105000-00004","volume":"13","author":"JM Dayer","year":"2001","unstructured":"Dayer, J. M. et al. Anti-interleukin-1 therapy in rheumatic diseases. Curr. Opin. Rheumatol. 13, 170\u2013176 (2001).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum2016166_CR109","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P","volume":"43","author":"Y Jiang","year":"2000","unstructured":"Jiang, Y. et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 43, 1001\u20131009 (2000).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016166_CR110","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1136\/ard.62.7.671","volume":"62","author":"R Rau","year":"2003","unstructured":"Rau, R., Sander, O. & Wassenberg, S. Erosion healing in rheumatoid arthritis after anakinra treatment. Ann. Rheum. Dis. 62, 671\u2013673 (2003).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016166_CR111","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1053\/sarh.2001.23701","volume":"30","author":"B Bresnihan","year":"2001","unstructured":"Bresnihan, B. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin. Arthritis Rheum. 30, 17\u201320 (2001).","journal-title":"Semin. Arthritis Rheum."},{"key":"BFnrrheum2016166_CR112","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1471-2474-12-153","volume":"12","author":"R Alten","year":"2011","unstructured":"Alten, R. et al. Efficacy and safety of the human anti-IL-1\u03b2 monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study. BMC Musculoskelet. Disord. 12, 153 (2011).","journal-title":"BMC Musculoskelet. Disord."},{"key":"BFnrrheum2016166_CR113","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4","volume":"43","author":"JA Mengshol","year":"2000","unstructured":"Mengshol, J. A. et al. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase and nuclear factor \u03baB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum. 43, 801\u2013811 (2000).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016166_CR114","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1210\/endo.139.3.5818","volume":"139","author":"K Kusano","year":"1998","unstructured":"Kusano, K. et al. Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology 139, 1338\u20131345 (1998).","journal-title":"Endocrinology"},{"key":"BFnrrheum2016166_CR115","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1172\/JCI117595","volume":"94","author":"MB Goldring","year":"1994","unstructured":"Goldring, M. B. et al. Interleukin-1 beta-modulated gene expression in immortalized human chondrocytes. J. Clin. Invest. 94, 2307\u20132316 (1994).","journal-title":"J. Clin. Invest."},{"key":"BFnrrheum2016166_CR116","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1042\/bj2270869","volume":"227","author":"JA Tyler","year":"1985","unstructured":"Tyler, J. A. Articular cartilage cultured with catabolin (pig interleukin 1) synthesizes a decreased number of normal proteoglycan molecules. Biochem. J. 227, 869\u2013878 (1985).","journal-title":"Biochem. J."},{"key":"BFnrrheum2016166_CR117","first-page":"481","volume":"9","author":"G Verbruggen","year":"1991","unstructured":"Verbruggen, G. et al. Influence of human recombinant interleukin-1 beta on human articular cartilage. Mitotic activity and proteoglycan metabolism. Clin. Exp. Rheumatol. 9, 481\u2013488 (1991).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum2016166_CR118","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1006\/excr.1995.1161","volume":"218","author":"FJ Blanco","year":"1995","unstructured":"Blanco, F. J. & Lotz, M. IL-1-induced nitric oxide inhibits chondrocyte proliferation via PGE2. Exp. Cell Res. 218, 319\u2013325 (1995).","journal-title":"Exp. Cell Res."},{"key":"BFnrrheum2016166_CR119","first-page":"65","volume":"110","author":"MG Attur","year":"1998","unstructured":"Attur, M. G. et al. Autocrine production of IL-1\u03b2 by human osteoarthritis-affected cartilage and differential regulation of endogenous nitric oxide, IL-6, prostaglandin E2, and IL-8. Proc. Assoc. Am. Physicians 110, 65\u201372 (1998).","journal-title":"Proc. Assoc. Am. Physicians"},{"key":"BFnrrheum2016166_CR120","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/art.1780400604","volume":"40","author":"JP Pelletier","year":"1997","unstructured":"Pelletier, J. P. et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum. 40, 1012\u20131019 (1997).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016166_CR121","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0002-9440(10)65368-0","volume":"154","author":"J Fernandes","year":"1999","unstructured":"Fernandes, J. et al. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am. J. Pathol. 154, 1159\u20131169 (1999).","journal-title":"Am. J. Pathol."},{"key":"BFnrrheum2016166_CR122","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/art.24096","volume":"61","author":"X Chevalier","year":"2009","unstructured":"Chevalier, X. et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 61, 344\u2013352 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016166_CR123","doi-asserted-by":"publisher","first-page":"R125","DOI":"10.1186\/ar3430","volume":"13","author":"SB Cohen","year":"2011","unstructured":"Cohen, S. B. et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res. Ther. 13, R125 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2016166_CR124","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1136\/ard.2009.113043","volume":"69","author":"M Attur","year":"2010","unstructured":"Attur, M. et al. Radiographic severity of knee osteoarthritis is conditional on interleukin 1 receptor antagonist gene variations. Ann. Rheum. Dis. 69, 856\u2013861 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016166_CR125","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.joca.2010.12.003","volume":"19","author":"HJ Kerkhof","year":"2011","unstructured":"Kerkhof, H. J. et al. Large-scale meta-analysis of interleukin-1 beta and interleukin-1 receptor antagonist polymorphisms on risk of radiographic hip and knee osteoarthritis and severity of knee osteoarthritis. Osteoarthr. Cartil. 19, 265\u2013271 (2011).","journal-title":"Osteoarthr. Cartil."},{"key":"BFnrrheum2016166_CR126","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1136\/ard.2009.120204","volume":"69","author":"GR Heiland","year":"2010","unstructured":"Heiland, G. R. et al. Synovial immunopathology in haemochromatosis arthropathy. Ann. Rheum. Dis. 69, 1214\u20131219 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016166_CR127","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1136\/annrheumdis-2012-202738","volume":"72","author":"A Latourte","year":"2013","unstructured":"Latourte, A., Frazier, A., Bri\u00e8re, C., Ea, H. K. & Richette, P. Interleukin-1 receptor antagonist in refractory haemochromatosis-related arthritis of the hands. Ann. Rheum. Dis. 72, 783\u2013784 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016166_CR128","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/ni.1935","volume":"11","author":"SL Masters","year":"2010","unstructured":"Masters, S. L. et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1\u03b2 in type 2 diabetes. Nat. Immunol. 11, 897\u2013904 (2010).","journal-title":"Nat. Immunol."},{"key":"BFnrrheum2016166_CR129","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.diabet.2013.07.003","volume":"39","author":"J Hensen","year":"2013","unstructured":"Hensen, J., Howard, C. P., Walter, V. & Thuren, T. Impact of interleukin-1\u03b2 antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial. Diabetes Metab. 39, 524\u2013531 (2013).","journal-title":"Diabetes Metab."},{"key":"BFnrrheum2016166_CR130","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","volume":"126","author":"PM Ridker","year":"2012","unstructured":"Ridker, P. M. et al. Effects of interleukin-1\u03b2 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a h IIb randomized, placebo-controlled trial. Circulation 126, 2739\u20132748 (2012).","journal-title":"Circulation"},{"key":"BFnrrheum2016166_CR131","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","volume":"162","author":"PM Ridker","year":"2011","unstructured":"Ridker, P. M., Thuren, T., Zalewski, A. & Libby, P. Interleukin-1\u03b2 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am. Heart J. 162, 597\u2013605 (2011).","journal-title":"Am. Heart J."},{"key":"BFnrrheum2016166_CR132","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.atherosclerosis.2014.07.012","volume":"236","author":"F Roubille","year":"2014","unstructured":"Roubille, F. et al. The interleukin-1\u03b2 modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model. Atherosclerosis 236, 277\u2013285 (2014).","journal-title":"Atherosclerosis"},{"key":"BFnrrheum2016166_CR133","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/j.1398-9995.2012.02843.x","volume":"67","author":"K Krause","year":"2012","unstructured":"Krause, K. et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy 67, 943\u2013950 (2012).","journal-title":"Allergy"},{"key":"BFnrrheum2016166_CR134","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1136\/annrheumdis-2012-202192","volume":"72","author":"HD De Koning","year":"2013","unstructured":"De Koning, H. D. et al. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome. Ann. Rheum. Dis. 72, 1634\u20131638 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016166_CR135","doi-asserted-by":"publisher","first-page":"114","DOI":"10.4065\/84.2.114","volume":"84","author":"JA Lust","year":"2009","unstructured":"Lust, J. A. et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1\u03b2-induced interleukin-6 production and the myeloma proliferative component. Mayo Clin. Proc. 84, 114\u2013122 (2009).","journal-title":"Mayo Clin. Proc."},{"key":"BFnrrheum2016166_CR136","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","volume":"71","author":"A G\u00fcl","year":"2012","unstructured":"G\u00fcl, A. et al. Interleukin-1\u03b2-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study. Ann. Rheum. Dis. 71, 563\u2013566 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016166_CR137","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bjd.13614","volume":"173","author":"B Mansouri","year":"2015","unstructured":"Mansouri, B., Richards, L. & Menter, A. Treatment of two patients with generalized pustular psoriasis with the interleukin-1\u03b2 inhibitor gevokizumab. Br. J. Dermatol. 173, 239\u2013241 (2015).","journal-title":"Br. J. Dermatol."},{"key":"BFnrrheum2016166_CR138","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2174\/157488412803305821","volume":"7","author":"N Pazyar","year":"2012","unstructured":"Pazyar, N., Feily, A. & Yaghoobi, R. An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases. Curr. Clin. Pharmacol. 7, 271\u2013275 (2012).","journal-title":"Curr. Clin. Pharmacol."},{"key":"BFnrrheum2016166_CR139","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/annrheumdis-2011-200743","volume":"71","author":"D Wendling","year":"2012","unstructured":"Wendling, D., Prati, C. & Aubin, F. Anakinra treatment of SAPHO syndrome: short-term results of an open study. Ann. Rheum. Dis. 71, 1098\u20131100 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2016166_CR140","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1007\/s00296-011-2020-x","volume":"32","author":"J Rech","year":"2012","unstructured":"Rech, J. et al. Adult-onset Still's disease and chronic recurrent multifocal osteomyelitis: a hitherto undescribed manifestation of autoinflammation. Rheumatol. Int. 32, 1827\u20131829 (2012).","journal-title":"Rheumatol. Int."},{"key":"BFnrrheum2016166_CR141","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.smim.2013.10.008","volume":"15","author":"CA Dinarello","year":"2013","unstructured":"Dinarello, C. A. & van der Meer, J. W. Treating inflammation by blocking interleukin-1 in humans. Semin. Immunol. 15, 469\u2013484 (2013).","journal-title":"Semin. Immunol."},{"key":"BFnrrheum2016166_CR142","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamadermatol.2014.5391","volume":"151","author":"KM Coleman","year":"2015","unstructured":"Coleman, K. M. et al. Open-label trial of MABp1, a true human monoclonal antibody targeting interleukin 1\u03b1, for the treatment of psoriasis. JAMA Dermatol. 151, 555\u2013556 (2015).","journal-title":"JAMA Dermatol."},{"key":"BFnrrheum2016166_CR143","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/344633a0","volume":"344","author":"DB Carter","year":"1990","unstructured":"Carter, D. B. et al. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 344, 633\u2013638 (1990).","journal-title":"Nature"},{"key":"BFnrrheum2016166_CR144","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1002\/art.23687","volume":"58","author":"HM Hoffman","year":"2008","unstructured":"Hoffman, H. M. et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndroms: results from two sequential placebo-controlled studies. Arthritis Rheum. 58, 2443\u20132452 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2016166_CR145","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/ncprheum0959","volume":"5","author":"LD Church","year":"2009","unstructured":"Church, L. D. & McDermott, M. F. Rilonacept in cryopyrin-associated periodic syndroms: the beginning of longer-acting interleukin-1 antagonism. Nat. Clin. Pract. Rheumatol. 5, 14\u201315 (2009).","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"BFnrrheum2016166_CR146","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2165\/11599820-000000000-00000","volume":"51","author":"A Chakraborty","year":"2012","unstructured":"Chakraborty, A. et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1\u03b2 monoclonal antibody. Clin. Pharmacokinet. 51, e1\u2013e18 (2012).","journal-title":"Clin. Pharmacokinet."},{"key":"BFnrrheum2016166_CR147","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4161\/mabs.3.1.13989","volume":"3","author":"AM Owyang","year":"2011","unstructured":"Owyang, A. M. et al. XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1\u03b2-mediated diseases. MAbs 3, 49\u201360 (2011).","journal-title":"MAbs"}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2016.166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2016.166","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2016.166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T03:29:35Z","timestamp":1692156575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2016.166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,10]]},"references-count":147,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["BFnrrheum2016166"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2016.166","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,10]]},"assertion":[{"value":"10 December 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}